ConductScience.org, home

Paper41270342

AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.

Tankou J and 10 others. Gynecol Oncol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer. Papers, record 41270342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41270342

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.
PubMed
Journal
Gynecol Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tankou JJo'an
2Ruau SSofia
3Walia AAnjali
4Toboni MMichael
5Noia HHollie
6Mullen MMaggie
7Lu KKevin
8Mutch DDavid
9Powell MAMatthew A
10Petricoin EFEmanuel F
11Fuh KCKatherine C

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Endometrial NeoplasmsMajor topic
Proto-Oncogene ProteinsMajor topic
TrastuzumabMajor topic
Receptor Protein-Tyrosine KinasesMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Female
Humans
Axl Receptor Tyrosine Kinase
Animals
Mice
Cell Line, Tumor
Xenograft Model Antitumor Assays
Erb-b2 Receptor Tyrosine Kinases
Drug Synergism
Cell Proliferation

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P50 CA265793NCI NIH HHSUnited StatesP50CA265793PubMed

Source NIH RePORTER

Download CSV of grants

References53

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120642839Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer.J Mol Signal2010https://conductscience.org/library/papers/20642839PubMed
224510676Preparation and use of reverse protein microarrays.Curr Protoc Protein Sci2014https://conductscience.org/library/papers/24510676PubMed
326153368The ImageJ ecosystem: An open platform for biomedical image analysis.Mol Reprod Dev2015https://conductscience.org/library/papers/26153368PubMed
437864955AXL - a new player in resistance to HER2 blockade.Cancer Treat Rev2023https://conductscience.org/library/papers/37864955PubMed
533049205Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer.Cancer Cell2020https://conductscience.org/library/papers/33049205PubMed
635546443Prognostic value of IGFBP2 in various cancers: a systematic review and meta-analysis.Cancer Med2022https://conductscience.org/library/papers/35546443PubMed
720861461Phosphorylation of threonine 154 in p40phox is an important physiological signal for activation of the neutrophil NADPH oxidase.Blood2010https://conductscience.org/library/papers/20861461PubMed
838726365Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer.iScience2024https://conductscience.org/library/papers/38726365PubMed
930741844Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.Int J Gynecol Pathol2020https://conductscience.org/library/papers/30741844PubMed
1025502142Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.Nat Commun2014https://conductscience.org/library/papers/25502142PubMed
1138132919First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.Cancer Med2024https://conductscience.org/library/papers/38132919PubMed
1224398671Cigarette sidestream smoke induces histone H3 phosphorylation via JNK and PI3K/Akt pathways, leading to the expression of proto-oncogenes.Carcinogenesis2014https://conductscience.org/library/papers/24398671PubMed
1335794161PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway.Sci Rep2022https://conductscience.org/library/papers/35794161PubMed
1420417484Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.Am J Obstet Gynecol2010https://conductscience.org/library/papers/20417484PubMed
1534407968Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.Clin Cancer Res2021https://conductscience.org/library/papers/34407968PubMed
1623816567Phosphorylation and degradation of S6K1 (p70S6K1) in response to persistent JNK1 Activation.Biochim Biophys Acta2013https://conductscience.org/library/papers/23816567PubMed
1739817679Cancer statistics, 2025.CA Cancer J Clin2025https://conductscience.org/library/papers/39817679PubMed
1819840887Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol2010https://conductscience.org/library/papers/19840887PubMed
1936239552Alarming trends and disparities in high-risk endometrial cancer.Curr Opin Obstet Gynecol2023https://conductscience.org/library/papers/36239552PubMed
2037773318ALK fusions in the pan-cancer setting: another tumor-agnostic target?NPJ Precis Oncol2023https://conductscience.org/library/papers/37773318PubMed

See all 53 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42835524AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer.iScience2026https://conductscience.org/library/papers/42835524

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41270342

GET https://conductscience.org/api/papers/v1/41270342/references?page=2